The Ribonucleic Acid Way

---

Riboway Therapeutics: Decoding RNA to precisely control protein expression/function.

We specialize in controlling how proteins are made by targeting RNA. Our smart RNA-targeting technology enables us to upregulate, downregulate, activate, or inhibit target proteins, depending on therapeutic needs. This flexibility is driven by our AI-based platform that decodes RNA regulation to identify druggable angles. So far, we have successfully validated 5 out of 5 targets attempted.

We have assets focusing on neurodegenerative diseases and metabolic diseases, including a first-ever ASO designed to activate a high-value, previously undruggable transcription factor. Our lead program, targeting the genetic cause of Spinocerebellar Ataxia Type 2 (SCA2), is a year to IND upon funding.

To receive a copy of our deck, please email deck@riboway.com.

If you'd like to get in touch with our team, please fill out the form below.

---

Riboway Therapeutics
700 Main Street, North
Cambridge, MA 02139